Table 1. Treatment regimen Day .... | American Society of Hematology

Table 1.

Treatment regimen

Day	Treatment
−23	Alemtuzumab test dose 3 mg IV*
−22	Alemtuzumab 10 mg IV†
−21	Alemtuzumab 15 mg IV†
−20	Alemtuzumab 20 mg IV†
−8	Fludarabine 30 mg/m² IV
−7	Fludarabine 30 mg/m² IV
−6	Fludarabine 30 mg/m² IV
−5	Fludarabine 30 mg/m² IV
−4	Fludarabine 30 mg/m² IV
−3	Melphalan 140 mg/m² IV; cyclosporine or tacrolimus dosed to maintain appropriate levels through day 100, and then tapered to day 180
−2	Rest
−1	Rest
0	Bone marrow infusion
1	Methotrexate 7.5 mg/m² IV
3	Methotrexate 7.5 mg/m² IV
6	Methotrexate 7.5 mg/m² IV
7	Methylprednisolone 1 mg/kg per day IV through day 28, and then taper granulocyte colony-stimulating factor 5 μg/kg body weight per day IV until absolute neutrophil count is ≥0.5 × 10⁹/L for 3 consecutive days

Day	Treatment
−23	Alemtuzumab test dose 3 mg IV*
−22	Alemtuzumab 10 mg IV†
−21	Alemtuzumab 15 mg IV†
−20	Alemtuzumab 20 mg IV†
−8	Fludarabine 30 mg/m² IV
−7	Fludarabine 30 mg/m² IV
−6	Fludarabine 30 mg/m² IV
−5	Fludarabine 30 mg/m² IV
−4	Fludarabine 30 mg/m² IV
−3	Melphalan 140 mg/m² IV; cyclosporine or tacrolimus dosed to maintain appropriate levels through day 100, and then tapered to day 180
−2	Rest
−1	Rest
0	Bone marrow infusion
1	Methotrexate 7.5 mg/m² IV
3	Methotrexate 7.5 mg/m² IV
6	Methotrexate 7.5 mg/m² IV
7	Methylprednisolone 1 mg/kg per day IV through day 28, and then taper granulocyte colony-stimulating factor 5 μg/kg body weight per day IV until absolute neutrophil count is ≥0.5 × 10⁹/L for 3 consecutive days

The test dose of alemtuzumab was administered 24 hours before the first dose, shown in this example on day −23.

†

Alemtuzumab treatment was required to be administered on 3 consecutive days but could begin on day −22, −21, or −20 and end on day −20, −19, or −18, respectively.

[ViewLarge]

This Feature Is Available To Subscribers Only